Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 544

Results For "IT"

10535 News Found

FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers
Drug Approval | September 16, 2025

FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers

Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo


Drug Hunter secures seed investment to scale drug discovery knowledge platform
R&D | September 16, 2025

Drug Hunter secures seed investment to scale drug discovery knowledge platform

Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management


GAIASO appoints Dr. Tracey Brown as CEO
People | September 16, 2025

GAIASO appoints Dr. Tracey Brown as CEO

Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,


Goa to host historic 10th Ayurveda day on September 23
News | September 16, 2025

Goa to host historic 10th Ayurveda day on September 23

We are taking Ayurveda to the world as a sustainable healthcare solution: Union Minister Prataprao Jadhav


MoS Health Patel inaugurates National Virus Research & Diagnostic Laboratory Conclave 2025
News | September 16, 2025

MoS Health Patel inaugurates National Virus Research & Diagnostic Laboratory Conclave 2025

Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem


Advent to sell generic drugmaker Zentiva to GTCR
News | September 16, 2025

Advent to sell generic drugmaker Zentiva to GTCR

Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business


FDA launches crackdown on deceptive drug advertising
Policy | September 16, 2025

FDA launches crackdown on deceptive drug advertising

The FDA is beginning rulemaking to close the “adequate provision” loophole